Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.45 |
| ▸ | CSF1R | P07333 | 3/20 | 0.45 |
| ▸ | MET | P08581 | 3/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 3/20 | 0.43 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2203252 | 0.80 | KDR (0.48) | KDRMETAURKATEKAURKB | |
| SCHEMBL378510 | 0.77 | KDR (0.59) | KDREGFRCSF1RMETMAPK14 | |
| SCHEMBL29693652 | 0.77 | KDR (0.59) | KDREGFRCSF1RMETMAPK14 | |
| SCHEMBL20525857 | 0.77 | KDR (0.50) | KDREGFRMETAURKATEK | |
| SCHEMBL2364278 | 0.77 | KDR (0.52) | KDRCSF1RMETAURKATEK | |
| SCHEMBL8554907 | 0.77 | KDR (0.55) | KDREGFRCSF1RMETMAPK14 | |
| SCHEMBL31324666 | 0.76 | PDGFRB (0.62) | KDRCSF1RMETMAPK14AURKA | |
| SCHEMBL29693548 | 0.76 | PDGFRB (0.62) | KDRCSF1RMETMAPK14AURKA | |
| SCHEMBL372681 | 0.76 | PDGFRB (0.62) | KDRCSF1RMETMAPK14AURKA | |
| SCHEMBL20525836 | 0.76 | AXL (0.49) | KDREGFRMETAURKATEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170896-A1 | c-Met modulators and methods of use | FLT4, MET, FLT1 | KDR 5/4885EGFR 166/4885CSF1R 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.